Education
About Us
Working with TipRanks
Follow Us
Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ:VNDA
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.57Last Year’s EPS
-0.07Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 13, 2025
|% Change Since: 1.28%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook, with significant revenue growth from Fanapt and successful integration of Ponvory, countered by a substantial decline in Hetlioz sales due to generic competition and increased net losses. The company's robust pipeline and strategic initiatives suggest potential for future growth, but operational and regulatory challenges raise concerns.Company Guidance
During the Q4 2024 earnings call for Vanda Pharmaceuticals, the company provided guidance indicating a strong growth trajectory, driven by products such as Fanapt, Hetlioz, and Ponvory. The company reported total revenues of $198.8 million for the full year 2024, marking a 3% increase from 2023. Fanapt net sales grew by 4% to $94.3 million, and Ponvory contributed $27.8 million in its first year of sales. However, Hetlioz sales declined 23% to $76.7 million due to generic competition. Vanda projected Fanapt revenues between $210 million and $250 million for 2025, a 6% to 26% increase, and set a 2030 target of over $750 million for its psychiatry portfolio and over $1 billion in total annual revenue. The company plans to further expand its sales force and invest in direct-to-consumer advertising to support growth.Fanapt Revenue Growth
Fanapt net product sales increased by 18% in Q4 2024 compared to Q4 2023, driven by new patient starts increasing by over 160%.
Ponvory Introduction Success
Ponvory net product sales reached $27.8 million for the full year 2024, indicating successful integration and market penetration following its acquisition.
Pipeline Expansion
Multiple new drug applications filed or planned for 2025, including Vantrela for bipolar I disorder and schizophrenia, and Imsidolimab for generalized pustular psoriasis.
Revenue Growth
Total revenues for Q4 2024 were $53.2 million, a 17% increase compared to Q4 2023, and full-year 2024 revenues were up by 3%.
---
VNDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VNDA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 13, 2025 | $4.70 | $4.42 | -5.96% |
| Nov 06, 2024 | $4.89 | $5.02 | +2.66% |
| Jul 31, 2024 | $5.84 | $5.64 | -3.42% |
| May 08, 2024 | $5.36 | $5.01 | -6.53% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Vanda Pharmaceuticals Inc. (VNDA) report earnings?
Vanda Pharmaceuticals Inc. (VNDA) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Vanda Pharmaceuticals Inc. (VNDA) earnings time?
Vanda Pharmaceuticals Inc. (VNDA) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VNDA EPS forecast?
VNDA EPS forecast for the fiscal quarter 2025 (Q1) is -0.57.
---